Resistance to therapies targeting the estrogen pathway remains a challenge in the treatment of estrogen receptor-positive breast cancer. To address this challenge, a systems biology approach was used. A library of small interfering RNAs targeting an estrogen receptor (ER)-and aromatase-centered network identified 46 genes that are dispensable in estrogen-dependent MCF7 cells, but are selectively required for the survival of estrogen-independent MCF7-derived cells and multiple additional estrogen-independent breast cancer cell lines. Integration of this information identified a tumor suppressor gene TOB1 as a critical determinant of estrogen-independent ER-positive breast cell survival. Depletion of TOB1 selectively promoted G1 phase arrest and sensitivity to AKT and mammalian target of rapmycin (mTOR) inhibitors in estrogen-independent cells but not in estrogen-dependent cells. Phosphoproteomic profiles from reverse-phase protein array analysis supported by mRNA profiling identified a significant signaling network reprogramming by TOB1 that differed in estrogen-sensitive and estrogen-resistant cell lines. These data support a novel function for TOB1 in mediating survival of estrogen-independent breast cancers. These studies also provide evidence for combining TOB1 inhibition and AKT/mTOR inhibition as a therapeutic strategy, with potential translational significance for the management of patients with ER-positive breast cancers.
INTRODUCTION
Breast cancer is the most common cancer among women in the United States and is the second leading cause of cancer-related deaths in this population. 1 Approximately 70% of newly diagnosed breast cancers express high levels of estrogen receptor-α (ERα), 2 a nuclear transcription factor that controls cell proliferation, in large part by regulating gene expression. ERα has also been described as having additional functions, including the regulation of growth factor signaling. 3 Anti-estrogens (AEs) and aromatase inhibitors (AIs) 4 are currently used to treat ER-positive breast cancer in pre-menopausal and post-menopausal women, respectively. AIs such as exemestane or anastrozole block the biosynthesis of the ERα ligand estrogen, whereas AEs such as tamoxifen or fulvestrant compete with estrogen for binding to ERα, in each case resulting in diminished ERα activity and in some cases diminished nuclear localization, leading to impaired cell proliferation and survival.
De novo and acquired drug resistance to AEs and AIs pose significant challenges to the effective treatment of ERα-positive breast cancers. Numerous resistance mechanisms have been identified, including epigenetic changes affecting the ERα promoter, 5 mutations activating the ERα protein-to-ligand independence, 6, 7 altered expression or activation of cellular signaling proteins that generally promote survival such as the epithelial growth factor receptor (EGFR), 8 insulin-like growth factor (IGF) receptor, 9 phosphatidylinositol 3-kinase (PI3K)/AKT, 10 mammalian target of rapmycin (mTOR) signaling 11 and nuclear factor-κ B, 12 and altered expression of specific miRNAs. 13 However, in hormone therapy-resistant breast cancer, chemotherapy remains the primary treatment modality 14 and the prognosis of such patients is poor.
To address this problem, we aimed to identify new points of vulnerability in estrogen-independent, AE/AI-resistant breast cancers. A number of studies have demonstrated that changes in the proximal signaling networks to proteins targeted by drugs are particularly common sources of resistance to the targeting agent. [15] [16] [17] The goal of this study was to use in-silico resources to develop a network centered on ERα and related ERs and aromatase, and then to create and probe a small interfering RNA (siRNA) library individually targeting genes in this network, to better understand the key mechanisms of estrogen independence and anti-estrogen resistance. Interrogation of the functional signaling consequences of this gene targeting was performed using a quantitative, highly multiplexed protein pathway activation mapping. These studies identified a group of genes with action specifically required for the survival of estrogenindependent cells. Strikingly, this work also demonstrated selective action of the tumor suppressor TOB1 (transducer of c-erbB2) as important for basal growth and drug resistance of estrogen-independent cell lines, based on distinctive regulation of survival and cell cycle signaling in these cell lines. These observations have potential translational significance for the management of ER-positive breast cancers.
RESULTS

Estrogen response-centered network
We hypothesized that loss of estrogen dependence would reflect an altered cellular requirement for genes closely linked to the core genes regulating estrogen response. A 631-protein estrogen response network (ERN) was developed around 5 seed proteins relevant to estrogen signaling: the ER genes ESR1 (ERα) and ESR2 (ERβ), the estrogen-related receptors ESRRA and ESRRG, and CYP19A1 (aromatase) (Figure 1a and Supplementary Table S1 ). For network construction, data for each of the five seeds were initially collected from public archives reporting protein-protein interactions, association in protein complexes, curated pathway information and estrogen-responsive genes. Protein-protein interaction databases (BIND, 18 BioGRID, 19 DIP, 20 HPRD, 21 IntAct 22 and MINT 23 ) were mined for the first and the second neighbors of the five seed proteins, both directly and via metasearch engines such as MiMI 24 and STRING. 25 Two hundred and forty-eight 'first neighbors', defined as proteins that directly interacted with a seed protein based on experimental data, constituted a high confidence core. Twelve proteins reported in the literature 26, 27 as complexed with ESR1, ESR2 or ESRRA were also included in the ER-centered network as a high-confidence core. We used multiple databases reporting ER signaling interactions, to identify 44 proteins as a pathway core. The Estrogen Responsive Gene Database 28 listed 38 highconfidence genes reported as manifesting altered transcriptional responses to an estrogen stimulus. Beyond these high-confidence cores, which in sum contributed 308 genes to the ERN, 323 additional genes were included based on their occurrence in at least two lower confidence sets (Figure 1a ). POLR2A  PSMD1  PSMB4  POLR2B  PSMC5  SF3A3  KIF1A  SCNN1A  RPS2  POLR2C  EIF3I  DDX54  TOB1  TAF2  CYR61  CDC2L1  BLOC1S1  NR2F1  PNRC1  PTK7  IER2  FANCG  PRPF6  FBP1  CNOT1   T47D  LCC1  LCC9  T47D-co  MDA-MB-231   MCF7  MCF10A  BT474  HFF1   Caspase 7 Activity (RFU)   ERH  IFRD2  NR2F1  FANCG  MED24  CELSR1  IKBKG  PRPF6  CYR61  PNRC1  POLR2C  IER2  JARID1  TFF1  G6PD  AP1B1  MXD1  PSMC5  PRKAR1B  CDC2L1  BAG1  PSMD1  KIF1A  FBP1  CLDN4  SIN3A  DUT  PTMA  SF3A3  CNOT1  PTK7  PRMT1  IRS1  NR2F1  TOB1  DDX54  SCNN1A  REXO4  TUBB  POLR2A  POLR2B  TAF2  BLOC1S1  PSMB4  EIF3I  MAPK12  PRKCD  RPS2  MAP2K3   20  15  10  5  1  20  15  10  5  1 Screening the ERN library identifies genes specifically required for viability in estrogen-independent cell lines To compare the cellular requirement for genes in the ERN in the context of decreased estrogen dependence and increased AE resistance, we used an siRNA library targeting the 631 genes in the ERN to screen four cell lines: MCF7, LCC1, LCC9 and human foreskin fibroblast (Supplementary Table S2 ). MCF7 is an estrogendependent breast adenocarcinoma cell line and is sensitive to treatment with the AEs tamoxifen and fulvestrant. The MCF7-derived cell line LCC1 was selected in vivo for estrogen independence, which commonly reflects AI resistance, but remains sensitive to tamoxifen and fulvestrant. LCC9, further derived by selection from LCC1 cells, is resistant to both tamoxifen and fulvestrant. 29, 30 Human foreskin fibroblasts do not depend on estrogen signaling and provided a control for non-specific inhibitors of cell viability. Analysis of primary hits indicated that LCC1 and LCC9 were significantly more susceptible to loss of viability following depletion of the ERN genes than were MCF7 or human foreskin fibroblast cells. The use of a biological cutoff of 50% viability or less identified 190 candidate hits for the LCC1 cells, 117 for LCC9 cells, 9 for MCF7 cells and 1 for human foreskin fibroblast-1 cells (Supplementary Figures S1A and B) .
Validation of hits obtained in LCC1 or LCC9 cells was performed using transfection of multiple siRNAs and confirmation of gene depletion by quantitative reverse transcriptase-PCR ( Supplementary Figures S1C-D) . Following validation, 85 genes were confirmed as important for viability in LCC1 cells, 65 in LCC9 cells and 3 in MCF7 cells; of these, 49 were common to LCC1 and LCC9, which included the 3 in MCF7 cells (Figure 1c and  Supplementary Tables S1 and S3) . Focusing on the genes required in LCC1 and/or LCC9, we assessed whether these genes selectively derived from specific categories of input to the ERN. This analysis indicated that this set was enriched for siRNAs targeting genes that either interacted directly with the five ERN seeds or included estrogen-responsive genes (Figure 1b) .
A subset of the 49 genes specifically required in LCC1 and LCC9 cells have previously been implicated as influencing viability in breast cancer or untransformed mammary cells (Figure 1d , see references in legend, and Supplementary Table S3) . A limited number of these genes have also been identified as contributing to cell proliferation and survival in additional cell types, suggesting they may be similarly important in breast cancers (Figure 1d ). Finally, Gene Ontology assignment 31, 32 suggested that the set of ERN genes specifically required in LCC1 and LCC9 cells was enriched in genes annotated for roles associated with RNA polymerase, the proteasome and mRNA splicing (Figure 1d ).
EIPS genes are selectively required for survival in multiple estrogen-independent cell lines We selected 25 genes from the LCC1/LCC9 viability group for more in-depth analysis (Supplementary Table S3 ) and defined them as estrogen-independent pro-survival (EIPS) genes. To determine whether their roles in viability were specific to cells of the MCF7 lineage, or more generally reflected a requirement in estrogen-independent versus estrogen-dependent cell lines, we analyzed the consequences of depletion in five additional breast cancer cell lines: MDA-MB-231 (triple negative, estrogen independent), T47D (ERα positive, estrogen dependent and tamoxifen/ fulvestrant sensitive), T47D-co (ERα positive, estrogen independent and tamoxifen/fulvestrant resistant), BT-474 (ERα positive, estrogen dependent) and MCF10A (similar to normal mammary epithelial cells) (Figure 1e) . Strikingly, this analysis indicated that the group of five estrogen-independent breast cancer cell lines MDA-MB-231, LCC1, LCC9, T47D-co and T47D clustered together in requiring EIPS genes for viability, in contrast to the estrogendependent cell lines MCF10A, MCF7 and BT474, in which the EIPS genes were generally less necessary for cell survival.
Knockdown of genes in the EIPS set might reduce cell viability by increasing apoptosis, decreasing cell proliferation, or both. Genes required for apoptosis resistance would be of particular interest as potential targets in cancer therapy, in contrast to those that primarily induce cytostasis. Activity levels of caspase 3/7 were assessed as surrogates for apoptotic induction following depletion of each of the EIPS genes. Knockdown of 15 genes in the group increased caspase 3/7 activities at least 2-fold in LCC1 cells, with 16 genes having such activity in LCC9 cells (Figure 1f ). In general, the degree of apoptotic induction associated with each gene in the set was comparable in the two lines, with knockdown of the transcription factor CNOT1, the polymerase II subunits POLR2B and POLR2C, and the proteasome component PSMB4 having the most significant effects. Finally, although LCC1 and LCC9 grow in an estrogen-independent manner, they retain ERα and other ERs, which may retain some biological activities. Potentially, the availability of estrogen might regulate the cell-survival effect of genes in the EIPS set. However, no significant difference in viability was observed in knocking down these genes in the LCC9 cells grown in the presence or the absence of 1 nM estradiol and only AP1B1  BAG1  BLOC1S1  CDK11B  CELSR1  CLDN4  CNOT1  CYR61  DDX54  DUT  EIF3I  ERH  FANCG  FBP1  G6PD  IER2  IFRD2  IKBKG  IRS1  KDM5A  KIF1A  MAP2K3  MAPK12  MED24  MXD1  NELFB  NR2F1  PNRC1  POLR2A  POLR2B  POLR2C  PRKAR1B  PRKCD  PRMT1  PRPF6  PSMB4  PSMC5  PSMD1  PTK7  PTMA  REXO4  RPS2  SCNN1A  SF3A3  SIN3A  TAF2  TFF1  TOB1  TUBB   MDA-MB-436   CAL51  BT549  MDA-MB-468   HS578T  MDA-MB-231   SKBR3  EVSAT  ZR-75-30  MDA-MB-175-VII   T47D  CAMA1  ZR-75-1  MDA-MB-361   KPL1  MCF7  BT474   14   9   4 estrogen-independent estrogen-dependent TOB1 supports breast cancer cell survival Y-W Zhang et al minimal differences were observed for a small number of genes in the LCC1 cells (Supplementary Figure S2) . Among the set of EIPS genes, we noted that TOB1 has been previously described as a transducer of ERBB2 signaling, is upregulated by ERBB2 and is linked to poor prognosis in nodenegative breast cancer. 33 These features have considerable relevance to estrogen resistance. Further, by comparing steadystate mRNA expression of 45 genes active in LCC1 and/or LCC9 in 9 estrogen-dependent and 8 estrogen-independent breast cancer cell lines (see Supplementary Table S4 for cell line information), TOB1 was one of the top 2 genes in which mRNA expression differed most significantly in estrogen-independent versus estrogen-dependent breast cancer cell lines (Figure 2a ), being higher in estrogen-dependent cell lines. In addition, TOB1 was amplified and/or overexpressed in 14% of 979 invasive breast cancers assembled in The Cancer Genome Atlas (Figure 2b and Supplementary Figure S3A ). In analysis of The Cancer Genome Atlas data, TOB1 and ESR1 mRNA expression and promoter methylation correlated positively, suggesting a particular relevance in this setting (Supplementary Figures S3B and C) . We also found significant correlation in the promoter methylation and mRNA expression for TOB1 and ERBB2, further supporting functional link between TOB1 and HER2 signaling.
Interestingly, overexpression of TOB1 was not sufficient to cause estrogen-independent proliferation of MCF7 cells. Figure S4) . Moreover, even higher concentrations of estradiol could not rescue the cell proliferation arrest induced by TOB1 knockdown (Supplementary Figure S5) . Interestingly, cell cycle analysis indicated a different basal compartmentalization, with MCF7 having a much higher proportion of cells in G1 phase (57% for MCF7 versus 34% for LCC1 and 37% for LCC9), and LCC1 and LCC9 enriched in S phase (25% for MCF7 versus 46% for LCC1 and 47% for LCC9) (Figures 3c and d) . As TOB1 inhibition has been previously reported to block G0/ G1-to-S transition, 34 we next investigated the effects of TOB1 knockdown on cell cycle distribution. siRNA depletion of TOB1 had a minimal impact on cell cycle distribution in MCF7 cells, but, unexpectedly, caused a significant arrest from G1 to S phase in LCC1 and LCC9 cells (Figures 3c and d) . Western blot analysis indicated that under steady-state growth conditions, the TOB1 protein was overexpressed (2.8-and 2.7-fold) in LCC1 and LCC9 cells as compared with that in MCF7 cells (Figure 3e ). This upregulation was transcriptional and partially post transcriptional, as TOB1 mRNA levels slightly increased in LCC1 and LCC9 cells (1.5 fold) (Supplementary Figure S6A) . Phosphorylation on TOB1 S164 has previously been associated with reduced anti-proliferative activity; 34 however, although there are higher levels of phosphorylated TOB1 in LCC1 and LCC9 cells (Figure 3f ), our analysis found no differences in the ratio of this phosphorylation versus total protein in MCF7 and LCC1 cells, but lower in LCC9 cells (Figure 3g ). The relative difference in regulatory phosphorylation in the two contexts implied an alternative explanation for differing TOB1 protein functionality associated with acquisition of estrogen independence.
Accordingly, we examined the effects of TOB1 knockdown on G1 regulatory proteins. TOB1 has been reported to inhibit cell cycle progression by negatively regulating cyclin D1 levels. 34, 35 Strikingly, depletion of TOB1 markedly elevated the expression of cyclin D1 in LCC1 and LCC9 cells as compared with that in MCF7 cells (Figures 4a and b) . In contrast, TOB1 knockdown increased p21 expression in all cell lines (Figures 4a-c) .
A number of studies have indicated that TOB1 expression regulates radiosensitivity and DNA-damage responses in cancer cells (for example, seeSuzuki et al. 36 ), based on actions with the DNA-repair machinery and in regulation of core survival signaling pathways. We found that basal levels of γ-H2AX (phosphorylated histone H2AX at serine 139), 37 an indicator of DNA damage, were higher in MCF7 than in LCC1 or LCC9 cells, but were equally enhanced by TOB1 knockdown in all three lines (Figures 4d-f ).
Defining differences in the TOB1-response network in estrogenindependent versus -dependent cells To extensively explore the roles of TOB1 in the survival of estrogen-independent cells and the impact on the signaling architecture of cancer-focused pathways, we then used reversephase protein array (RPPA) analysis to profile the basal expression and activation/phosphorylation of 76 key signaling proteins in MCF7, LCC1 and LCC9 cells (Supplementary Figure S7A) . Not surprisingly, cultured MCF7 cells exhibited significant differences from their estrogen-independent counterparts, with significantly less activation of important EGFR network proteins such as mTOR, STAT3, S6 kinase, Shc, EGFR, ERBB2, PTEN and ERBB3. MCF7 cells also demonstrated relative activation of other signaling molecules such as Mek1/2, c-Abl, c-Kit, Stat5, IGF-1 receptor and B-Raf. The estrogen-independent cell lines exhibited fewer variations between each other, but there was more activation of Bad, Met, VEGFR2 and Aurora kinase A/B/C in LCC9 cells than in LCC1 cells. In order to focus the difference of estrogen-independent versus estrogen-dependent cells, molecules that were common in LCC1 and LCC9, but significantly different in MCF7 cells, were uploaded for canonical pathway enrichment and network analysis Table S4 ). Data are obtained from the Cancer Cell Line Encyclopedia. 4 Unsupervised clustering was performed using MeV. The color scale represents mRNA levels with the darkest blue indicating the lowest level and the darkest yellow indicating the highest level. Red arrows indicate top two genes with the most significant different expression between estrogen-dependent and -independent cell lines. Figures S7B and C) . As shown, the ERBB signaling pathway and its related PI3K/AKT, Erk/mitogen-activated protein kinase and mTOR signaling pathways were changed in estrogenindependent cells versus MCF7 cells.
We next performed RPPA analysis in MCF7, LCC1 and LCC9 cells 48 h after siRNA depletion of TOB1 or a negative control siRNA ( Figure 5 and Supplementary Figure S8) . Figure 5a describes the expressions of each unmodified or phosphorylated protein in MCF7, LCC1 and LCC9 as a function in the absence (siNeg) and the presence (siTOB1) of TOB1 depletion. Figure 5b then describes the fold changes in protein or phosphorylated expression in each cell line as a specific consequence of TOB1 depletion. Consistent with the data shown in Figure 4 , RPPA analysis confirmed that p21 and cyclin D1 were upregulated by TOB1 knockdown. In order to address the differing responses to TOB1 inhibition in estrogenindependent cells versus estrogen-dependent cells, two groups of molecules were further analyzed. The first group included molecules that were activated by TOB1 knockdown in estrogenindependent cells, but reduced in MCF7 cells, such as Src, ERBB2, protein kinase C, ERBB3, AMPKa, Erk1/2 and IGF-1 receptor/IR (Figure 5b, underlined) . The second group contained 4EBP1, MEK1/2, CREB (cAMP-response element binding protein), FADD (Fas-associated protein with death domain) and Ki67, which were inactivated or downregulated by siTOB1 in estrogen-independent cells, but activated in MCF7 cells (Figure 5b , black frame). The canonical pathway enrichment and network analysis of these genes identified that the TOB1-response network in estrogenindependent cells differed from the parental estrogen-dependent MCF7 cells. The ERBB, growth hormone, IGF-1 receptor and mTOR signaling pathways were selectively activated by TOB1 knockdown in estrogen-independent cells (Figures 5c and e) . In contrast, thefibroblast growth factor signaling and death receptor pathways were inactivated by TOB1 inhibition in LCC1 and LCC9 cells (Figures 5d and e) .
In addition, we used reverse transcriptase-PCR to analyze a panel of 84 genes relevant to ER signaling for mRNA changes in 
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LCC1_siNeg LCC1_siTOB1 LCC9_siNeg LCC9_siTOB1 Figure S9) . We first asked which genes showed statistically distinct changes in mRNA expression in the LCC1 and LCC9 versus the MCF7 cells (Supplementary Figures  S9A and B) . We then asked which of these changes were reversed in cells following knockdown of TOB1 (Supplementary Figures S9C  and D) ; and in addition, which genes showed distinctive patterns of response to TOB1 knockdown, whether they originally differed in expression in the MCF7 versus LCC1 and LCC9 cell lines or not ( Supplementary Figures S9B and D) . As these data indicate, a number of genes relevant to the proliferation of survival of breast tumors have significantly altered expression in the LCC1 and LCC9 versus the MCF7 cell line, including those relevant to transforming growth factor-β/bone morphogenetic protein, WNT, mitogen and invasion signaling (TGFB3, IGFBP5, BMP4, WISP2, NRP1 and others); the ER itself (ESR1) is induced in the resistant cell lines. Of this group of genes significantly altered in the ER-resistant derivative lines, knockdown of TOB1 did reverse changes in the expression of some, such as WISP2, FOS, CYP19A and TGFA. However, this effect of TOB1 depletion was only seen in LCC1 cells, not in LCC9 cells, and hence is not directly linked to action of TOB1 in the context of resistance to estrogen. However, in comparing the effect of TOB1 knockdown in the broader list of ER-associated genes, it was notable that this knockdown caused significant reduction of expression of genes such as the ER-interacting protein NROB2, the differentiation-promoting factor WNT5A and a small set of other genes in MCF7 cells, but not in LCC1 or LCC9 cells. These data suggest that one action of TOB1 may be conditioning the landscape of genes available to support the estrogen signaling apparatus.
TOB1 interaction with AKT/mTOR survival signaling differs in MCF7 versus LCC1 and LCC9 cells, influencing response to pathwaytargeted agents TOB1 overexpression has been reported to reduce MEK/ERK-and AKT-dependent signaling, 38 which is potentially relevant to a selective role in estrogen independence. 10 Moreover, RPPA data and canonical pathway analysis identified that the mTOR signaling pathway was activated by TOB1 knockdown in LCC1 and LCC9 cells ( Figure 5 ). We next asked whether TOB1 might influence the response of these cells to inhibitors of mTOR (rapamycin), AKT (AZD5363) or MEK/ERK (U0126). Knockdown of TOB1 significantly sensitized LCC1 and LCC9 cells to rapamycin (Figures 6b and c) and AZD5363 (Figures 6e and f) , while having no effect on response to U0126 ( Figure S10 and, importantly, no effect on response to any drug in MCF7 cells (Figures 6a-d) . Therefore, TOB1 knockdown in estrogen-independent breast cancer cells potentiates the anti-tumor effects of clinically relevant signaling inhibitors in this setting. These data also demonstrated that in LCC1 and LCC9 cells, TOB1 has proliferative functions parallel with AKT and mTOR signaling pathways, but in the same signaling pathway as ERK.
Finally, TOB1 is known to regulate ERBB2/HER2 signaling, raising the possibility that the inhibition of ERBB2 may phenocopy the effect of depleting TOB1. We compared the effect of lapatinib, a small molecule inhibitor of ERBB2 and ERBB1/EGFR, versus other targeted signaling proteins, in MCF7 versus LCC1 and LCC9 cells (Supplementary Figure S11) . Lapatinib had no effect in MCF7 cells, but in both LCC1 and LCC9 cells, 10 μM lapatinib reduced proliferation to 30% of untreated cells, representing an effect similar to that of TOB1 knockdown. However, in the siTOB1-transfected cells, no significant sensitization to lapatinib was observed when compared with siNEG control cells. This pattern was distinctive and was likely due to the action of lapatinib against ERBB2/HER2, as we also assessed inhibitors of a group of kinases in the HER2 pathway, including EGFR, RAS and MEK, and no such distinguishing difference was identified in cells treated with the EGFR inhibitor erlotinib (Supplementary Figure S11) . These data indicated that the proliferative function of TOB1 is involved in ERBB2-related signaling.
DISCUSSION
The issue of estrogen independence is of great importance in the clinical management of breast cancer. Using a functional genomics screening strategy, we show that numerous genes in an estrogen response-centered network are engaged when estrogen-dependent breast cancer cells develop estrogen independence. One of those genes, TOB1, was selected for deeper analysis because of its potential interactions with other important signaling proteins relevant to breast cancer, and because of its overexpression in some ER-dependent tumors. A focused protein pathway activation mapping approach underpinned by protein phosphorylation analysis and mRNA profiling then provided quantitative information about the activation levels of canonical cell line-specific signaling events. This approach also assessed the effects of TOB1 knockdown on those targets and pathways, and identified signaling changes caused by TOB1 knockdown in estrogen-independent cells. In initially estrogen-dependent tumors, once AE selection is applied, elevated expression of TOB1 based on transcriptional and posttranscriptional mechanisms is associated with the development of resistance.
Intriguingly, besides showing that the ability of TOB1 to influence the activity of canonical effectors such as cyclin D1 differs between estrogen-dependent and -independent cells, our work identifies an extended chain of signaling proteins culminating with different expression profiles of estrogen-related genes that are differentially influenced by TOB1 in these two environments. Our data also show that depletion of TOB1 selectively sensitizes estrogen-independent cells to clinically important inhibitors of AKT and mTOR. Given the growing evidence linking Rapamycin (μM) Figure 6 . Effects of TOB1 knockdown on the cytotoxicity of mTOR and AKT inhibitors in MCF7, LCC1 or LCC9 cells. SiNEG or siTOB1-transfected cells were plated into 96-well plates and treated with the mTOR inhibitor, Rapamycin, or the AKT inhibitor, AZD5363, at varying concentrations for 144 h. Cell viability was determined by the CellTiter-Blue method. Cell viability after rapamycin treatment in negative control or TOB1 siRNA-transfected MCF7 (a), LCC1 (b) and LCC9 (c) cells. Upper panels, cell viability; bottom panels, sensitization index. Cell viability after AZD5363 treatment in siNEG-or siTOB1-transfected MCF7 (d), LCC1 (e) and LCC9 (f) cells. Upper panels, cell viability; bottom panels, sensitization index.
TOB1 supports breast cancer cell survival Y-W Zhang et al elevated expression of TOB1 to invasive breast cancers (Figure 2b ), these studies provide important and unexpected insights into potentially targetable mechanisms that underlie a problem that is at the core of many breast cancer deaths. This is the first study to link TOB1 to the biology of estrogen resistance, as its initial identification was as a growth inhibitory protein that becomes less active in cells overexpressing ERBB2 (Matsuda et al. 39 ). Erk1/2 and its downstream substrate p90RSK1 could phosphorylate TOB1, relieving its growth inhibitory activity. 34, 40 In our studies, the activation of ERBB2 and Erk1/2 by TOB1 inhibition indicated a reverse feedback from a downstream target (Figure 7b, right panel) . Interestingly, another downstream target of ERBB2 signaling, the PI3K/AKT/mTOR pathway, was activated by TOB1 knockdown in estrogenindependent cells. It is plausible that TOB1 functions in parallel with the PI3K/AKT/mTOR pathway, because TOB1 knockdown potentiates the effects of AKT or mTOR inhibitors. Moreover, TOB1 inhibition reduced activation of the CREB, which is PI3K/Akt dependent. 41 Coupled transcriptional analysis also indicated that TOB1 depletion differentially affected the expression profile of estrogen pathway-related genes, some of which were relevant to the mitogenic signaling pathways identified in RPPA analysis, further reinforcing the importance of these pathways. In particular, the mRNA expression differences suggest that one action of TOB1 may be conditioning the landscape of genes available to support proliferation and survival signaling.
In addition, the G1/S arrest induced by TOB1 inhibition, which is mediated by the upregulation of p21, indicates TOB1 supports estrogen-independent cell growth by promoting G1/S cell cycle transition and suggests that cells treated with siTOB1s might senesce, 42 because TOB1 inhibition could not induce apoptosis ( Figure 1f ). As summarized in Figure 7 , TOB1 has a proliferative function in a growth factor receptor network in estrogenindependent cells. Briefly, the transition from estrogen dependence (Figure 7a ) to estrogen independence (Figure 7b, left panel) uses growth factors including EGFR, the ERBB family and IGF-1 receptor, to activate at least two pathways that promote estrogenindependent cell proliferation. One is mediated by PI3K/AKT, which regulates translation and transcription of proliferative genes (reviewed in Hennessey et al. 43 ), and cell cycle progression to support estrogen-independent growth. The second signaling pathway, which is downstream of these growth factors, is mediated through Ras/Raf/mitogen-activated protein kinase signaling. 44, 45 TOB1 is phosphorylated by Erk1/2 to promote estrogen-independent proliferation by facilitating G1/S cell cycle transition. TOB1 is also involved in CREB1 activation to regulate its impact on target gene transcription. When TOB1 is knocked down (Figure 7b , right panel), these pro-proliferative activities are reversed, in concert with p21-mediated G1/S arrest.
Various AE agents have been employed in sequence to address the estrogen independence and acquisition of AE resistance that lead to relapse and eventual death in many women with ER+ breast cancer. Despite a wealth of information about specific mechanisms that might be attacked, [5] [6] [7] [8] [9] [10] [11] [12] [13] 46 the context in which those mechanisms are addressed (typically as a monotherapy and rarely in combinations designed to disable resistance mechanisms) is so complex that additional resistant cell subpopulations almost always emerge to defeat these therapies. Recent studies show that AEs can be combined with cell cycle-directed treatments with promising anti-tumor activity. 47, 48 Such data are in accord with our studies and that of many others showing activation of components of the ERBB signaling network in hormone-resistant breast cancer cells. Our data suggest that many proteins are likely to collaborate to generate this estrogenresistant phenotype, making it imperative to identify critical nodes that can be interdicted alone, or in combination to disable this process. Our work identified that TOB1 supports the estrogenindependent cell survival, and that its function is closely linked to that of ERBB2/HER2, with HER2 inhibition partially phenocopying TOB1 knockdown. However, although TOB1 is not the sole The TOB1-related signaling pathways in estrogen-independent cells. Left: briefly, growth factor receptors including EGFR, ERBB family, IGF-1R and so on activate two pathways to promote estrogen-independent cell proliferation. One is mediated by PI3K/AKT, which regulates translation and transcription of proliferative genes, and cell cycle progression, then supports estrogenindependent growth. Ras/Raf/mitogen-activated protein kinase (MAPK) mediates the second signaling pathway downstream of the growth factor receptors. TOB1 is phosphorylated by Erk1/2 to promote estrogen-independent proliferation by facilitating G1/S cell cycle phase transition. Right: in the presence of TOB1 inhibition, upregulation of p21 results in G1/S arrest. In addition, transcription can be inhibited by TOB1 knockdown. Reduction of CreB1 phosphorylation by TOB1 inhibition can reduce its proliferative target gene transcription and then inhibit cell growth. However, growth factor receptors such as ERBB2 and IGF-1R are activated as a reverse feedback mechanism, the PI3/AKT pathway is activated by TOB1 inhibition. Inhibition of AKT or mTOR potentiates the effects of TOB1 inhibition on cell proliferation in estrogenindependent cells.
mediator of estrogen independence, its known anti-proliferative functions within the ERBB signaling network 33, 34, 40 argue for its further study to investigate how it and its collaborating proteins might be disabled to prevent the emergence of estrogen independence in ER+ breast cancer. In the future, it will be important to extend the analysis of TOB1 and the signaling paradigm identified in this study to the analysis of other independent systems for intrinsic versus acquired estrogen resistance.
These studies demonstrate the diversity and flexibility of survival mechanisms, as breast cancer cells develop estrogen independence. Interestingly, many different genes contribute to survival in this setting, challenging previous conventions that estrogen independence and resistance to AE drugs involve the gradual accumulation of resistance mechanisms. As TOB1 is not an identified druggable target, these results cannot be validated in vivo at this time. However, the translational significance of this new molecular mechanism of estrogen independence in human breast cancer will be fully determined when TOB1 inhibitors are developed to enable in-vivo validation studies.
MATERIALS AND METHODS
Cell culture and chemicals
Cell lines used in these studies are from Lombardi Comprehensive Cancer Center, Georgetown University (Washington, DC, USA). Cells are tested for mycoplasma negative. For information on medium and assay reagents used for each cell line, see Supplementary Information. HEK293T cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 2 mM L-glutamine. Cell lines were maintained at 37°C and 5% CO 2 . Estradiol was obtained from Sigma (St Louis, MO, USA) and prepared at 1 mM in ethanol. AZD5363 and rapamycin were purchased from Selleckchem (Houston, TX, USA) and prepared at 10 mM in dimethylsulfoxide. Drug stock aliquots were kept at − 20°C. All drugs were diluted to desired concentrations in full medium immediately before each experiment. The final dimethylsulfoxide concentrations did not exceed 0.1%.
RNA interference screening
An ER-centered network was developed using the open-source software tool Cytoscape, using methods described in detail in Astsaturov et al.
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The ER-centered siRNA library was custom-ordered from Qiagen (Germantown, MD, USA) in a 96-well plate format with a single well representing one of the 631 genes identified as part of the ER-centered network. Each well contained two pooled siRNAs, targeting different sequences of the same gene. siRNAs were re-suspended in RNase-free water at 1 μM. Cell density and transfection reagent for cells were listed in Supplementary Information Cells were reversed transfected with the ER-centered siRNA library at 20 nM and incubated for 144 h. Viability for each targeted gene was measured as described below and normalized to a median value of 14 non-silencing controls on the plate. In each cell line, RNA interference screening were repeated three or four times. siRNA validation Viability data from three or four experimental replicate experiments were statistically analyzed. Those siRNAs with adjusted P o 0.05 were considered to be significantly different from the siNEG control and were considered to be hits if they caused at a loss of 50% viability or more in target cell lines, as reflecting a robust biological effect. Using this cut-off, only about 1% of all gene knockdowns met the criteria for hits in the estrogen-dependent MCF7 cell line. For each hit identified, four different siRNAs (Qiagen) targeting the same gene were tested for validation studies in individual wells. Two out of the four siRNAs were the same target sequences as the siRNAs in the screen, when available. The other two siRNAs were new sequences to test. Cells were screened as described above. If at least two out of four of the siRNAs tested reduced viability by at least 50%, the candidate passed validation as a putative hit.
Caspase 7 activity
Cells were reverse transfected with siRNAs at 20 nM in triplicate and incubated for 120 h. Caspase 7 activity was measured using Apo-ONE as described by Promega (G7790, Madison, WI, USA). Caspase 7 activity for each gene knockdown was calculated by normalizing to median fluorescence values of non-silencing controls on the plate.
Reverse-phase protein array TOB1 or negative scrambled siRNAs with a final concentration of 10 nM were reverse transfected into cells for 48 h. At each sample, triplicates of each transfection were collected for RPPA analysis. 49 Antibodies used for RPPA were listed in Supplementary Information.
Bromodeoxyuridine incorporation
After 30 min of pulse labeling with 50 μM bromodeoxyuridine (BD Biosciences, San Jose, CA, USA), cells were collected, stained with fluorescein isothiocyanate-conjugated anti-bromodeoxyuridine antibody (BD Biosciences, 347583) and analyzed with a FACScan flow cytometer (BD Biosciences). 50 Western blotting Cells were washed with ice-cold phosphate buffered saline and lysed. Twenty-five to~50 μg of protein was used for western blotting. Primary antibodies against TOB1 (ab79372) and phosphorylated-TOB1 (ab78915) were purchased from Abcam, Inc. (Boston, MA, USA). Antibodies against glyceraldehyde-3-phosphate dehydrogenase (5174), p21 (2947) and cyclin D1 (2922) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-phosphorylated-H2AX (γH2AX, clone JBW301) was purchased from Upstate Biotech (Millipore, Billerica, NY, USA). Shown are the representative data from separate experiments. Images were processed by Adobe Photoshop software (San Jose, CA, USA).
Cell viability assay
CellTiter Blue (Promega, G8081) viability assay or CellTiter 96 AQueous One Solution Cell Proliferation assay (Promega, 3582) was used to measure cell viability according to the manufacturer's manuals. For crystal violet staining method, cells were stained with 0.52% crystal violet for 10 min and rinsed with ddH 2 O. Crystal violet was dissolved with 100 mM sodium citrate and absorbance at 570 nm was read. Cell viability was calculated as a percentage of the untreated cells.
TOB1 overexpression in MCF7 cells
TOB1 contained within pLOC-TURBO RFP lentiviral constructs were obtained from Thermo Scientific Open Biosystems (OHS5834-EG10140, Pittsburgh, PA, USA). HEK293T cells were transfected at 60%-70% confluence with 6 μg pLOC-TOB1 (or empty vector), 3 μg psPAX2 and 0.3 μg VSV-G plasmids using FuGENE6 transfection reagent (Promega, E2691). Cells were infected at 30% confluence using 3 ml virus containing media, 1 ml normal growth media and 3.2 μg of polybrene. Media was replaced 24 h following transduction with normal growth media and at 48 h with media containing blasticidin S (Sigma; 15205, 10 μg/ml for MCF7 cells and 11 μg/ml for LCC1 and LCC9 cells). Selection continued for 7 days and TOB1 overexpression was confirmed by western blotting.
